CLINICAL_TRIALS
trial_result
· 2019-01-15
Clinical Trial Update: Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease [Phase 2]
Summary
Phase 2 trial evaluating PF-06649751 in early-stage Parkinson's disease was terminated with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Parkinson Disease | Phase 2 | Status: TERMINATED | Results posted: 2019-01-15